Fig. 5
From: Nanomaterials in tumor immunotherapy: new strategies and challenges
DOX-PLGA-NPs against tumor by inducing effects of chemotherapy and immunotherapy. DOX-PLGA-NPs, a kind of immunogenic cell death (ICD) inducer, can be introduced into CT-26 tumor cells and inhibit tumor growth in vivo by eliciting cytotoxicity and HMGB1 release. Besides, DOX-PLGA-NPs stimulate a tumor cell-specific immune response by releasing damage-associated molecular patterns (DAMPs), which promotes DC maturation and increases cytotoxic T lymphocytes tumor infiltration, causing an ICD-based specific anti-tumor immune response, finally, tumor cell death